Dara Jospé


Legal Influencer

Q1| 2022

Legal Influencers

Lexology’s Legal Influencers programme recognises firms and authors that provide excellent content within a work area and region. Find out more

  • Q1| 2022 in Healthcare and life sciences - Canada
  • Q2 | 2021 in Healthcare and life sciences - Canada


Results 16 to 20 of 78

PMPRB releases 2022-23 departmental plan in the wake of successful legal challenges and postponements

Canada - April 6 2022 On March 3, 2022, the Patented Medicine Prices Review Board (the “PMPRB” or the “Board”) released its 2022-23 Departmental Plan [PDF] outlining its…

Eric Saragosa

Key Takeaways from ongoing PMPRB litigation

Canada - February 28 2022 Since the August 2019 amendments to the Patented Medicines Regulations (the “Amendments”), three cases challenging the Patented Medicine Prices…

Eric Saragosa

Quebec Court of Appeal Renders Major Decision on the PMPRB

Canada - February 21 2022 In a much-anticipated decision, which will likely have a substantial impact on the pharmaceutical industry in Canada, the Quebec Court of Appeal…

Mathieu Gagné

La Cour d’appel du Québec rend une décision importante sur le CEPMB

Canada - February 20 2022 Dans une décision très attendue qui aura probablement un impact important sur l’industrie pharmaceutique au Canada, la Cour d’appel du Québec a…

Mathieu Gagné

A first step to national pharmacare? CADTH invites stakeholders to comment on potential pan-Canadian formulary framework

Canada - February 14 2022 In Canada, coverage for prescription drugs currently exists through an array of public and private drug plans. To ensure accessibility of drugs to…

Lina Bensaidane